FDA Approves Elfornithine for the Treatment of High-Risk Neuroblastoma in Adult, Pediatric Patients

This is the first FDA approval for a therapy intended to reduce the risk of relapse in patients with high-risk neuroblastoma.

Related Keywords

Breck Jones ,Kristen Gullo , ,